These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 24111840)
21. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
22. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942 [TBL] [Abstract][Full Text] [Related]
23. Breast cancer susceptibility variants alter risks in familial disease. Latif A; Hadfield KD; Roberts SA; Shenton A; Lalloo F; Black GC; Howell A; Evans DG; Newman WG J Med Genet; 2010 Feb; 47(2):126-31. PubMed ID: 19617217 [TBL] [Abstract][Full Text] [Related]
24. Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens. Rassi H; Houshmand M; Hashemi M; Majidzadeh K; Akbari MH; Panahi MS Tsitol Genet; 2008; 42(2):55-62. PubMed ID: 18630122 [TBL] [Abstract][Full Text] [Related]
25. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer. Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236 [TBL] [Abstract][Full Text] [Related]
26. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800 [TBL] [Abstract][Full Text] [Related]
27. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Duffy SW; Chen HH; Tabar L; Day NE Stat Med; 1995 Jul; 14(14):1531-43. PubMed ID: 7481190 [TBL] [Abstract][Full Text] [Related]
28. Application of Multi-State Model in Analyzing of Breast Cancer Data. Vasheghani Farahani M; Ataee Dizaji P; Rashidi H; Mokarian F; Biglarian A J Res Health Sci; 2020 Jan; 19(4):e00465. PubMed ID: 32291364 [TBL] [Abstract][Full Text] [Related]
29. Estimation of sojourn time in chronic disease screening without data on interval cases. Chen TH; Kuo HS; Yen MF; Lai MS; Tabar L; Duffy SW Biometrics; 2000 Mar; 56(1):167-72. PubMed ID: 10783792 [TBL] [Abstract][Full Text] [Related]
30. Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors. Wu YY; Yen MF; Yu CP; Chen HH Br J Cancer; 2013 Jun; 108(11):2241-9. PubMed ID: 23674086 [TBL] [Abstract][Full Text] [Related]
31. Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. Hsu CY; Yen MF; Auvinen A; Chiu YH; Chen HH Stat Methods Med Res; 2018 Aug; 27(8):2519-2539. PubMed ID: 29984633 [TBL] [Abstract][Full Text] [Related]
32. Sampling-based Markov regression model for multistate disease progression: Applications to population-based cancer screening program. Hsu CY; Hsu WF; Yen AM; Chen HH Stat Methods Med Res; 2020 Aug; 29(8):2198-2216. PubMed ID: 31744392 [TBL] [Abstract][Full Text] [Related]
33. Estimation of age of onset and progression of breast cancer by absolute risk dependent on polygenic risk score and other risk factors. Bhatt R; van den Hout A; Antoniou AC; Shah M; Ficorella L; Steggall E; Easton DF; Pharoah PDP; Pashayan N Cancer; 2024 May; 130(9):1590-1599. PubMed ID: 38174903 [TBL] [Abstract][Full Text] [Related]
34. Multistate models for the natural history of cancer progression. Cheung LC; Albert PS; Das S; Cook RJ Br J Cancer; 2022 Oct; 127(7):1279-1288. PubMed ID: 35821296 [TBL] [Abstract][Full Text] [Related]
35. Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. Crowther MJ; Lambert PC Stat Med; 2017 Dec; 36(29):4719-4742. PubMed ID: 28872690 [TBL] [Abstract][Full Text] [Related]
36. A multistate survival model of the natural history of cancer using data from screened and unscreened population. Bhatt R; van den Hout A; Pashayan N Stat Med; 2021 Jul; 40(16):3791-3807. PubMed ID: 33951215 [TBL] [Abstract][Full Text] [Related]
37. Multistate models and lifetime risk estimation: Application to Alzheimer's disease. Brookmeyer R; Abdalla N Stat Med; 2019 Apr; 38(9):1558-1565. PubMed ID: 30511460 [TBL] [Abstract][Full Text] [Related]
38. State selection in Markov models for panel data with application to psoriatic arthritis. Thom HH; Jackson CH; Commenges D; Sharples LD Stat Med; 2015 Jul; 34(16):2456-75. PubMed ID: 25739994 [TBL] [Abstract][Full Text] [Related]
39. Inference of Onset Age of Preclinical State and Sojourn Time for Breast Cancer. Wu D; Kim S Med Res Arch; 2022 Feb; 10(2):. PubMed ID: 35419489 [TBL] [Abstract][Full Text] [Related]
40. Building a predictive breast cancer risk model. Johnson CM; Ensor J; Broglio K; Smolenski D; Ravdin P; Amos C; Meric-Bernstam F; Brewster A; Bevers T; Arun B; Berry D AMIA Annu Symp Proc; 2007 Oct; ():995. PubMed ID: 18694095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]